WU KONG1
WU-KONG1: Primary Analysis of a Phase II Study of Sunvozertinib in Patients With Previously Treated Advanced NSCLC and an EGFR Exon 20 Insertion Mutations

Released: June 06, 2024

Expiration: June 05, 2025

Activity

Progress
1
Course Completed